CureVac NV (Germany) Performance
| 5CV Stock | EUR 2.76 0.07 2.60% |
The firm shows a Beta (market volatility) of 0.0514, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CureVac NV's returns are expected to increase less than the market. However, during the bear market, the loss of holding CureVac NV is expected to be smaller as well. CureVac NV right now shows a risk of 3.4%. Please confirm CureVac NV treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if CureVac NV will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CureVac NV has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, CureVac NV is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 1.3 B | |
| Total Cashflows From Investing Activities | -127.9 M |
CureVac |
CureVac NV Relative Risk vs. Return Landscape
If you would invest 284.00 in CureVac NV on August 31, 2024 and sell it today you would lose (8.00) from holding CureVac NV or give up 2.82% of portfolio value over 90 days. CureVac NV is currently producing 0.0126% returns and takes up 3.3987% volatility of returns over 90 trading days. Put another way, 30% of traded stocks are less volatile than CureVac, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CureVac NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CureVac NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CureVac NV, and traders can use it to determine the average amount a CureVac NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0037
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 5CV |
Estimated Market Risk
| 3.4 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CureVac NV is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CureVac NV by adding CureVac NV to a well-diversified portfolio.
CureVac NV Fundamentals Growth
CureVac Stock prices reflect investors' perceptions of the future prospects and financial health of CureVac NV, and CureVac NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CureVac Stock performance.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.34 | |||
| Profit Margin | (1.26) % | |||
| Operating Margin | (7.27) % | |||
| Current Valuation | 792.23 M | |||
| Shares Outstanding | 221.98 M | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 13.59 X | |||
| Revenue | 102.99 M | |||
| EBITDA | (386.49 M) | |||
| Cash And Equivalents | 1.33 B | |||
| Cash Per Share | 7.34 X | |||
| Total Debt | 55.28 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 3.29 X | |||
| Cash Flow From Operations | (733.13 M) | |||
| Earnings Per Share | (0.63) X | |||
| Total Asset | 1.16 B | |||
About CureVac NV Performance
By analyzing CureVac NV's fundamental ratios, stakeholders can gain valuable insights into CureVac NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CureVac NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CureVac NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people.Things to note about CureVac NV performance evaluation
Checking the ongoing alerts about CureVac NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CureVac NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CureVac NV had very high historical volatility over the last 90 days | |
| The company reported the revenue of 102.99 M. Net Loss for the year was (411.72 M) with loss before overhead, payroll, taxes, and interest of (135.09 M). | |
| CureVac NV has accumulated about 1.33 B in cash with (733.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 46.0% of the company shares are owned by insiders or employees |
- Analyzing CureVac NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CureVac NV's stock is overvalued or undervalued compared to its peers.
- Examining CureVac NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CureVac NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CureVac NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CureVac NV's stock. These opinions can provide insight into CureVac NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |